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CLINICAL SCIENCE
Patient Self-Reported Adherence to Ritonavir-Boosted
Darunavir Combined With Either Raltegravir or Tenofovir
Disoproxil Fumarate/Emtricitabine in the
NEAT001/ANRS143 Trial
Adriana Ammassari, MD,* Wolfgang Stöhr, PhD,† Andrea Antinori, MD,* Jean-Michel Molina, PhD,‡
Christine Schwimmer, PhD,§ Pere Domingo, MD,║ Anders Thalme, MD, PhD,¶ Massimo Di Pietro, MD,#
Cedrick Wallet, MSc,§ Anton Pozniak, MD,** Laura Richert, PhD,§ and François Rafﬁ, MD, PhD,††
the NEAT001/ANRS143 Trial Study Group
Background: The NEAT001/ANRS143 trial demonstrated non-
inferiority of ritonavir-boosted darunavir combined with either ral-
tegravir (RAL + DRV/r) or tenofovir disoproxil fumarate/
emtricitabine (TDF/FTC + DRV/r) in HIV-positive, antiretroviral-
naive adults. In post hoc analyses, however, RAL + DRV/r showed
inferiority in patients with baseline CD4+ ,200/mm3 and HIV-1
RNA$100,000 copies per milliliter. This preplanned ancillary study
was conducted to assess whether differences in adherence might
explain efﬁcacy results.
Setting: Phase III, open-label, randomized, multicenter study in 15
European countries (ClinicalTrials.gov, NCT01066962).
Methods: Seven hundred seventy-four participants self-reported
adherence (modiﬁed AIDS Clinical Trials Group questionnaire) over
96 weeks [383 RAL + DRV/r (twice daily; 5 pills/day), 391 TDF/FTC
+ DRV/r (once daily; 4 pills/day)]. Primary endpoint was $95%
versus ,95% adherence to prescribed doses recorded (1) over the last
4 days or (2) on the visual analogue scale over the last 30 days.
Results: Characteristics, except age, were similar between arms;
9% had CD4+ ,200 cells/mm3 and HIV-1 RNA $100,000 copies
per milliliter. Adherence $95% in the last 4 days (P = 0.029) or at
the visual analogue scale (P = 0.0072) was higher with TDF/FTC +
DRV/r than with RAL + DRV/r. Adherence $95% over the last 4
days was associated with lower probability of virological failure (P =
0.015). Adherence in patients with baseline CD4+ ,200 cells/mm3
and HIV-1 RNA $100,000 copies per milliliter was similar to the
rest of the population, and not signiﬁcantly associated with efﬁcacy
measures, with no signiﬁcant differences between arms.
Conclusion: Adherence was high and slightly better in the TDF/
FTC + DRV/r than in the RAL + DRV/r arm. No convincing
evidence was found that higher failure rate in the RAL + DRV/r arm
in the subgroup with worse baseline viroimmunological status is
caused by adherence differences.
Key Words: adherence, HIV, antiretrovirals, NtRTI-sparing regi-
men, raltegravir, darunavir/ritonavir
(J Acquir Immune Deﬁc Syndr 2018;79:481–490)
INTRODUCTION
Treatment of HIV infection relies on combination
antiretroviral therapy (ART), which is highly effective in
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achieving control of HIV replication, in recovering immune
deﬁciency and thus in allowing for improved life expec-
tancy.1 Nevertheless, effectiveness of ART may be hampered
by suboptimal adherence to medication intake.2 Many factors,
which may be related to the patient, the circumstances and the
treatment, may impede drug intake exactly as prescribed. It
has been widely demonstrated that a negative impact on
medication adherence is mainly driven by 2 factors: com-
plexity of the regimen, determined by repeated daily dosing
and number of pills, and treatment side effects.3,4 In an era
with more convenient antiretroviral (ARV) regimens, pa-
tients’ perceived side effects and treatment convenience or
satisfaction are becoming the most important factors for
sustained adherence.5
Also, in clinical trials, adherence to study medications is
essential for reaching study outcomes and may inﬂuence trial
results. ARVs are highly efﬁcacious in suppressing HIV but
associated with low adherence rates and may eventually lead to
low virologic efﬁcacy and selection of drug resistance
compromising future treatment options. The NEAT001/
ANRS143 study was a phase 3, open-label, noninferiority,
randomized, multicenter clinical trial comparing the efﬁcacy
and safety of the nucleotide reverse-transcriptase inhibitor
(NtRTI)-sparing regimen of ritonavir-boosted darunavir (DRV/
r) plus raltegravir (RAL) with the standard triple drug regimen of
DRV/r plus tenofovir disoproxil fumarate/emtricitabine (TDF/
FTC) for ﬁrst-line combination ART in HIV adults naive to
ARVs.6 Notably, the 2 study arms were different in respect to
number of daily dosages and pills with a higher complexity
burden in the RAL + DRV/r than in the TDF/FTC + DRV/r arm.
The ﬁnal results, obtained in 805 patients with a median of 123
weeks of follow-up, showed noninferiority of the NtRTI-sparing
regimen compared with the standard treatment. In prespeciﬁed
subgroup analysis, this ﬁnding was conﬁrmed for patients with
CD4+ cells.200 cells/mm3,whereas in patients with,200 cells/
mm3, the RAL + DRV/r arm was inferior to the standard triple
regimen. A nonsigniﬁcant difference toward more failures in the
NtRTI-sparing treatment groupwas also observed in patientswith
baseline HIV-1 RNA of 100,000 copies per milliliter or more. A
post hoc analysis indicated that the inferiority of the NtRTI-
sparing regimenwas restricted to patients with baseline CD4+ cell
count ,200/mm3 and HIV-1 RNA $100,000 copies per
milliliter. It may be possible that in this patient subgroup,
composed of more difﬁcult-to-treat patients with advanced HIV
disease, nonadherence behaviors may have played a relevant role.
The preplanned ancillary study on patient self-reported
adherence to ARVs was conducted to compare levels and time
trends of different adherence measures by treatment arms, to
evaluate association of adherence with virological failure, and
particularly to assess whether differences in adherence to RAL
+ DRV/r or TDF/FTC + DRV/r might explain subgroup
efﬁcacy results in the NEAT001/ANRS143 trial.
METHODS
Study Design and Participants
The NEAT001/ANRS143 trial was a phase III, open-
label, randomized trial performed in 15 European countries.
The full study design and procedures are described elsewhere.6
Eight hundred ﬁve ARV-naive adults were randomized in a 1:1
ratio to receive either 2 pills of darunavir 400 mg and ritonavir
100 mg once daily combined with 1 pill of raltegravir 400 mg
twice daily (5-pill twice-daily regimen) or 1 pill of tenofovir/
emtricitabine 245/200 mg ﬁxed-dose combination once daily
(4-pill once-daily regimen). In agreement with the principles of
the Helsinki declaration, the Ethics Committee of each
participating center approved the study protocol, and all study
patients gave written informed consent. The study was
registered with ClinicalTrials.gov, number NCT01066962.
Adherence Assessment and Procedures
Adherence assessment was based on patient-reported
measures, and participants were asked to complete a modiﬁed
version of the AIDS Clinical Trials Group questionnaire.7 This
was considered useful based on literature showing that best
estimate of adherence should be based on a combination of
several measures.8 The following questions were asked: Please
report the number of doses of your anti-HIV medications you
have eventually missed over the last 4 days (for each drug,
number of doses missed “yesterday”; “2 days ago”; “3 days
ago”; and “4 days ago”); How closely did you follow your
timing-speciﬁc schedule? (more than 2 hours deviation over
the last week; response options: “never,” “some of the time”;
“about half of the time”; “most of the time”; and “all of the
time”); Did you interrupt your anti-HIV medications in the
absence of provider input (response options: “no”; “yes”) and
in case of afﬁrmative answer number of days with missed
medications (response options: “1 day”; “2 days,” “3–4 days”;
“5–6 days”; and “$7 days”); What was the adherence to your
anti-HIV medications over the last 30 days? (response options
on a visual analogue scale [VAS] from 0 [not taken any dose of
the anti-HIV medication] to 100% [taken every single dose]).
On average, participants needed 5 minutes to ﬁll the question-
naire. Patients were asked to complete the adherence question-
naire at 5 study visits after the start of study medications: week
(W) 04, W12, W24, W48, and W96. The questionnaires were
centralized in sealed anonymous envelopes, so that site staff
remained unaware of the patient’s replies. Blood samples were
obtained concomitantly. CD4 cell counts and viral loads in
plasma were measured at local laboratories with commercially
available viral load assays, with no change in the kits
throughout the trial.6
Adherence Endpoints Outcomes
The percentage of prescribed ARVs taken during the
previous 4 days was calculated as: (1 ‒ [number of self-
reported missed doses/number of doses prescribed])*100. Of
note, the number of doses (tablets) prescribed in 4 days was
different in the 2 treatment arms: 16 in the TDF/FTC + DRV/r
arm and 20 in the RAL + DRV/r arm. For both number of
doses taken/prescribed and the VAS, the primary endpoint
was predeﬁned as $95% versus ,95% adherence. Further-
more, predeﬁned adherence categories were ,80%, $80–
95%, $95–99%, and 100%. As secondary endpoints, “no
timing deviation” was deﬁned as reporting to follow the
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timing-speciﬁc schedule “all of the time” versus all other
categories together. We also analyzed timing deviations as
ordered variable but did not ﬁnd any differences and so we
did not report the results. Unplanned treatment interruptions
since the last visit were analyzed as “yes” (ie, any inter-
ruptions) versus “no,” and as ordered categories.
Statistical Analyses
The 2 arms of the trial were compared as randomized
according to and based on available data. As secondary
analysis, participants were analyzed per-protocol with cen-
soring when any component of the initial randomized trial
treatment was stopped. The primary endpoint was compared
between the 2 randomization arms across all study visits
using generalized estimating equation (GEE) models. Sec-
ondary endpoints were the variation of adherence at different
time points of follow-up and determination of the level of
adherence required for successful virological suppression
among the 2 treatment arms. Possible determinants of
adherence across study visits were analyzed using GEE
models, including time on ART, sex, age, mode of HIV
infection (homosexual/bisexual men versus other route of
transmission), ethnicity (white versus nonwhite), country,
baseline CD4+ cell count, and baseline HIV-1 RNA. The
association between adherence measures and time to virolog-
ical failure was evaluated by using Cox regression with time-
updated adherence in univariable and multivariable models
(using the same factors as described above). Conﬁrmed
virological failure was deﬁned as change of any component
of the initial randomized regimen before week 32 because of
documented insufﬁcient virological response (deﬁned as
reductions of less than 1 log10 copies per milliliter in HIV-1
RNA by week 18 or HIV-1 RNA 400 copies per milliliter or
higher at week 24); failure to achieve virological response by
week 32 (deﬁned as HIV-1 RNA concentrations of 50 copies
per milliliter or higher); and HIV-1 RNA concentrations of 50
copies per milliliter or higher at any time after week 32. All
virological components of the primary endpoint had to be
conﬁrmed by a second measurement.6
In post hoc analyses, we also looked at the association
of adherence with the primary endpoint of the NEAT001/
ANRS143 trial, which was time to virological or clinical
failure.6 Patients with failure before the ﬁrst adherence
assessment were excluded in these analyses. Because in
NEAT001/ANRS143 higher failure rates in the RAL + DRV/
r arm were seen in those with CD4+ cells,200 cells/mm3 and
HIV-1 RNA $100,000 copies per milliliter at baseline, we
examined whether adherence was lower in this subgroup or
whether, in this subgroup, the association with HIV-1 RNA
suppression/virological failure differed between the random-
ization arms. Statistical analyses were performed using Stata
Statistical Software Release 14 (StataCorp, College
Station, TX).
RESULTS
Between August 2010 and September 2011, 805
treatment-naive adults were enrolled into the NEAT001/
ANRS143 trial and randomized to RAL + DRV/r (n = 401)
or TDF/FTC + DRV/r (n = 404). Of these, 10 withdrew before
the ﬁrst adherence assessment at week 4. Additional 21
participants (13 in the RAL-DRV/r arm and 8 in the TDF/
FTC + DRV/r arm) did not provide any adherence data after
W0 and were excluded from the adherence analyses (character-
istics of these patients were similar to the whole study
population; data not shown). Of the remaining 774 participants,
310 (40%), 227 (29%), 96 (12%), 76 (10%), and 65 (8%) had
5, 4, 3, 2, and 1 adherence assessments, with no differences
between the treatment arms. Baseline characteristics of the 774
participants retained in analysis were broadly similar between
the 2 treatment groups (383 RAL + DRV/r and 391 TDF/FTC
+ DRV/r), except for a small difference in age. 72/774 (9%)
patients had CD4+ cells ,200 cells/mm3 and HIV-1 RNA
$100,000 copies per milliliter, with no differences in the 2
treatment arms (Table 1). During follow-up, 55 (7%) patients
discontinued any component of their randomized regimen for
any reason for more than 30 days between randomization and
their last adherence assessment (RAL + DRV/r: n = 33; TDF/
FTC + DRV/r: n = 22). The proportion of patients who had
discontinued was similar in the 2 treatment arms with overall
percentages of ,0.5%, 1%, 2%, 4%, and 8% at W04, W12,
W24, W48, and W96, respectively.
Medication Adherence Overall and by
Treatment Arm
Adherence by treatment arm as assessed by the different
adherence measurements is shown in Figure 1 and a summary
over all visits in Table 2.
Number of Doses Taken Over the Last 4 Days
Across all visits, the percentage of participants who
have taken $95% of their medications was higher in the
TDF/FTC + DRV/r arm and ranged from 91% to 93%
compared with 87% to 91% in the RAL + DRV/r arm [odds
ratio (OR) 1.43; 95% conﬁdence interval (CI): 1.04 to 1.97; P
= 0.029]. Results were similar when analyzing drugs taken in
the 4 ordered categories ,80%, $80–95%, $95–99%, and
100% (OR 1.71; 95% CI: 1.14 to 2.58; P = 0.0096). Overall
adherence and the difference between the arms did not change
over time (no signiﬁcant statistical interaction between arm
and time). When looking at individual drugs, we found no
difference between the arms in adherence to DRV or ritona-
vir. Although in the TDF/FTC + DRV/r arm, there was no
difference in adherence to DRV, ritonavir, and TDF/FTC, in
the RAL + DRV/r arm, adherence to RAL was slightly lower
than to DRV or ritonavir (proportion of patients with $95%
of medication taken across all visits was 88% for RAL versus
91% for DRV/r; P , 0.001).
Adherence on the Visual Analogue Scale
The proportion of patients with $95% of prescribed
medication taken over the last 30 days ranged from 90% to
92% without difference between the arms (P = 0.66).
However, patients in the TDF/FTC + DRV/r arm had
signiﬁcantly better adherence across all visits when compared
with the RAL + DRV/r arm (OR 1.55; 95% CI: 1.13 to 2.13;
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P = 0.0072). Adherence in both arms was decreasing over
time (P , 0.0001): 100% adherence at weeks 04, 24, and 96
was reported in 88%, 77%, and 71% in TDF/FTC + DRV/r,
and in 76%, 71%, and 67% in RAL + DRV/r.
Of note, concordance for the adherence category of
$95% between adherence in the last 4 days and VAS across
all visits was 88%, with no difference between the
randomization arms.
Following the Timing-Speciﬁc Schedule Over the
Last Week
The proportion of patients with no timing deviation of
more than 2 hours ranged from 45% to 50%, with a trend for
better adherence in the TDF/FTC + DRV/r compared with the
RAL + DRV/r arm (OR 1.26; 95% CI: 0.99 to 1.62; P =
0.06), and no signiﬁcant change over time (P = 0.45). Across
all visits, 16% patients reported to have never followed the
timing schedule, 13% some of the time, 2% half of the time,
and 21% most of the time (P = 0.53 for comparison of arms).
Unplanned Treatment Interruptions After the
Last Visit
Across all visits, no treatment interruption was reported
in 92% with no statistically signiﬁcant difference between the
arms (P = 0.30); on 5%, 1%, 1%, ,0.1%, and 0.6% of visits,
treatment interruptions of 1 day, 2 days, 3–4 days, 5–6 days,
or $7 days were reported. Of note, treatment interruptions
were more frequently reported with longer follow-up (P =
0.008) and were 6%, 9%, and 11% at weeks 04, 24, and 96
across both arms.
Adherence by Treatment Arm and
Viroimmunological Parameters
When comparing medication adherence between pa-
tients with different baseline CD4+ cell count (,200 versus
$200 cells/mm3) or baseline HIV-1 RNA (,100,000 versus
$100,000 copies per milliliter), there were no signiﬁcant
differences in any of the adherence measures, neither overall
nor differential in the 2 study arms (no statistically signiﬁcant
interaction with treatment arms; results not shown). There
were also no differences when comparing participants with
CD4+,200 cells/mm3 and HIV-1 RNA$100,000 copies per
milliliter with the rest of the study population (Table 2).
Among participants with at least 1 adherence measure-
ment, virological suppression at HIV-1 RNA ,50 copies per
milliliter was achieved at W04 in 26% of cases (12% in the
TDF/FTC + DRV/r arm; 40% in the RAL + DRV/r arm), and
at W12 in 63% of cases (48% in the TDF/FTC + DRV/r arm;
78% in the RAL + DRV/r arm). Thereafter, the proportion of
patients with HIV RNA ,50 copies per milliliter was similar
in the 2 arms with overall percentages of 84%, 86%, 91%,
92%, 93%, and 91% at weeks 24, 32, 48, 64, 80, and 96,
respectively. The associations between adherence and HIV-1
RNA ,50 copies per milliliter at the time of assessment are
summarized in Table 1, Supplemental Digital Content http://
links.lww.com/QAI/B212.
Association of Adherence Measures With
Virological Failure and Primary Endpoint
The analysis of adherence measures and virological
failure according to the virological component of the main
TABLE 1. Baseline Characteristics of the Study Population
Shown by Randomization Arm
Factor
RAL +
DRV/r
TDF/FTC +
DRV/r Overall
Pn = 383 n = 391 n = 774
Sex, male, n (%) 339 (89) 345 (88) 684 (88) 0.61
Age, yr, n (IQR) 37 (31–45) 39 (31–46) 38 (31–46) 0.035
Ethnicity, n (%) 0.60
Nonwhite 50 (13) 44 (11) 94 (12)
White 315 (82) 324 (83) 639 (83)
Other 18 (5) 23 (6) 41 (5)
Mode of HIV
infection, n (%)
0.68
Homosexual/
bisexual
258 (67) 270 (69) 528 (68)
Heterosexual 90 (23) 92 (69) 182 (23)
Other/unknown 35 (9) 29 (7) 64 (8)
CD4+ nadir, cells/
mm3, n (IQR)
320 (240–376) 309 (249–370) 311 (244–373) 0.35
CD4+, cells/mm3,
n (IQR)
336 (261–394) 328 (248–406) 333 (257–400) 0.29
HIV-1 RNA, log10
copies per
milliliter, n
(IQR)
4.8 (4.3–5.2) 4.7 (4.3–5.1) 4.8 (4.3–5.1) 0.43
CD4+ (cells/mm3)
and HIV-1 RNA
(log10 copies per
milliliter)
categories,
n (%)
0.37
CD4 + $200,
HIV-1 RNA
, 100,000
222 (58) 246 (63) 468 (60)
CD4 + ,200,
HIV-1 RNA
, 100,000
23 (6) 21 (5) 44 (6)
CD4 + $200,
HIV-1 RNA
$ 100,000
104 (27) 86 (22) 190 (25)
CD4 + ,200,
HIV-1 RNA
$ 100,000
34 (9) 38 (10) 72 (9)
Country, n (%) 1.0
France 109 (28) 115 (29) 224 (29)
Italy 57 (15) 55 (14) 112 (14)
Germany 47 (12) 50 (13) 97 (13)
United
Kingdom
46 (12) 50 (13) 96 (12)
Spain 37 (10) 37 (9) 74 (10)
Belgium 26 (7) 26 (7) 52 (7)
Other country 61 (16) 58 (15) 119 (15)
P value is from comparisons between RAL + DRV/r and TDF/FTC + DRV/r arms
using t test (continuous variables) or x2 test (categorical variables).
IQR, interquartile range.
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trial’s primary endpoint deﬁnition included 770 patients with
111 virological failures (Table 3). We found that patients with
$95% of doses taken in the last 4 days had a lower risk of
virological failure (univariable hazard ratio [HR] 0.54; 95%
CI: 0.33 to 0.89; P = 0.015), with no difference between the 2
arms (P value of the interaction term 0.19). Unplanned
treatment interruptions (any versus none; the same for time
of interruption in ordered categories, results not shown),
never .2 hours timing deviations, or $95% adherence
during the last 30 days on the VAS were not associated with
virological failures. For all adherence measures, multivariable
analyses gave similar results, as did analyses censoring
patients after switch from their allocated regimen (results
not shown).
In addition to virological failure, we analyzed the
relationship between adherence measures and the primary
endpoint of the NEAT001/ANRS143 trial including also
clinical failures (122 failures, of which 104 were virological
failures), and found similar associations.
We then repeated the analyses for the subgroup with
baseline CD4+ ,200 cells/mm3 and HIV-1 RNA $100,000
copies per milliliter, where higher failure rates had been seen
in the RAL + DRV/r arm compared with the TDF/FTC +
DRV/r arm. No signiﬁcant associations of adherence with
virological failure or the primary endpoint were observed. In
the RAL + DRV/r arm, for this speciﬁc group of patients, the
HR was,1 and lower for all 4 adherence measures compared
with all patients in the RAL + DRV/r arm and with
participants in the TDF/FTC + DRV/r arm suggesting that
in this subgroup, good adherence might be more relevant than
in the TDF/FTC + DRV/r arm; however, P values were
not signiﬁcant.
Factors Associated With Adherence
Multivariable analyses conﬁrmed the associations
described above between speciﬁc adherence measures and
randomization arm and time on study (Table 4). In addition,
older age was signiﬁcantly associated with better medication
adherence (except time deviation). We also found that
nonwhites had signiﬁcantly worse adherence than whites
across various measures (except treatment interruptions), and
that adherence signiﬁcantly differed between countries. We
did not ﬁnd an association of any of the adherence measures
with either sex, or baseline CD4+ cell count, or baseline HIV-
1 RNA.
DISCUSSION
Adherence to ART, the key determinant of virological
response is a very complex parameter because it reﬂects
human behavior and as such varies from 1 patient to another
FIGURE 1. Adherence by treatment arms as assessed by different adherence measurements.
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and can change over time. In the NEAT001/ANRS143 study,
ART-naive subjects on average self-reported high levels of
adherence to study drugs in both treatment arms. More in
depth analysis of adherence behaviors showed for the TDF/
FTC + DRV/r group compared with the RAL + DRV/r group
signiﬁcantly higher adherence rates at all time points in 3 of 4
adherence measures (number of doses taken over the last 4
days, 30 days of adherence on the VAS, and deviation from
timing-speciﬁc schedule). The only adherence measure
signiﬁcantly associated with time to virological failure or
the primary endpoint of the NEAT001/ANRS143 trial
including also clinical failures was ,95% adherence at
short-term patient recall (ie, “doses taken in the last 4 days”),
with no difference between the 2-arm subgroups based on
viroimmunological baseline status; we did not see signiﬁcant
differences in any of the adherence measures, neither overall
nor differential in the 2 study arms.
The threshold of .95% adherence to prescribed doses
and tablets was established as a requirement for achieving
virological suppression with ﬁrst-generation unboosted pro-
tease inhibitors, a class with short half-live, low genetic
barrier to resistance development, and limited forgiveness.9
Further studies showed that adherence and virological
suppression improved with simpliﬁed regimens and lower
pill burden, although in a meta-analysis of 19 studies
published through March 2013, patients on once-daily
regimens did not achieve virological suppression more
frequently than patients on twice-daily regimens.10 Impact
of adherence behavior might also depend on the drug class
considered. With ritonavir-boosted protease inhibitors, aver-
age adherence was a better determinant of virological success
than was the duration or frequency of treatment interruption,
whereas for non-nucleoside reverse-transcriptase inhibitors,
consecutive missed doses were associated with the highest
risk of virological failure.11–13 RAL is a well-tolerated and
effective drug that demonstrated durable virological suppres-
sion in ﬁrst-line ART through 240 weeks of therapy.14
However, because of its twice-daily formulation, RAL may
be highly susceptible to various nonadherence behaviors,
such as selective morning or evening dose skipping, short
treatment interruptions, and suboptimal levels of adherence.
These patterns are common in clinical practice.15 In a pro-
spective study assessing the patterns of adherence to RAL-
based regimens, longer treatment interruption and average
adherence were both independently associated with virolog-
ical failure.16 Of note, TDF/FTC is considered as the most
forgiving N(t)RTI combination because of the very prolonged
intracellular half-lives of the 2 drugs.17
Our study seems to conﬁrm the importance of high
adherence levels (ie, .95%) on likelihood of virological
success. Keeping in mind that self-reported adherence may
overestimate real drug intake attributing virological failure to
differences in efﬁcacy between treatment arms and leading to
incorrect study conclusions, the only adherence measure
associated with virological failure was self-reporting ,95%
of doses taken/prescribed in the past 4 days, with no
difference between treatment arms. These results, suggesting
that adherence in the past 4 days had a greater impact on
TABLE 2. Adherence Summary
100% of Doses Taken No Timing Deviation
No Treatment
Interruption 100% on the VAS ‡95% of Doses Taken ‡95% on the VAS
RAL +
DRV/r
TDF/FTC
+ DRV/r
RAL +
DRV/r
TDF/FTC
+ DRV/r
RAL +
DRV/r
TDF/FTC
+ DRV/r
RAL +
DRV/r
TDF/FTC
+ DRV/r
RAL +
DRV/r
TDF/FTC
+ DRV/r
RAL +
DRV/r
TDF/FTC
+ DRV/r
Adherence over all
visits*
Always 266
(70%)
304 (78%) 58 (15%) 76 (19%) 296
(77%)
283 (72%) 157
(41%)
187 (48%) 277
(72%)
304 (78%) 298
(78%)
296 (76%)
Sometimes 108
(28%)
78 (20%) 216
(56%)
227 (58%) 78 (20%) 100 (26%) 191
(50%)
175 (45%) 99 (26%) 78 (20%) 73 (19%) 85 (22%)
Never 9 (2%) 9 (2%) 109
(28%)
88 (23%) 9 (2%) 8 (2%) 35 (9%) 29 (7%) 7 (2%) 9 (2%) 12 (3%) 10 (3%)
Total no. of visits
with this level of
adherence
1265
(87%)
1392 (92%) 645
(45%)
747 (50%) 1323
(92%)
1363 (91%) 1003
(70%)
1163 (78%) 1288
(89%)
1392 (92%) 1308
(91%)
1373 (92%)
Adherence by
baseline CD4+
cells and HIV-1
RNA†
CD4+ $200/mm3
or HIV-1 RNA
,100,000
171/1335
(87%)
111/1365
(92%)
729/1325
(45%)
689/1358
(49%)
105/1327
(92%)
131/1358
(90%)
412/1324
(69%)
306/1352
(77%)
150/1335
(89%)
111/11,365
(92%)
118/1324
(91%)
113/1352
(92%)
CD4+ ,200/mm3
and HIV-1
RNA
$100,000
13/114
(89%)
11/149
(93%)
64/113
(43%)
70/148
(53%)
11/112
(90%)
12/148
(92%)
23/114
(79%)
30/147
(79%)
11/114
(90%)
11/149
(93%)
12/114
(89%)
13/147
(91%)
Interaction test of
baseline strata
with arm
P = 0.96 P = 0.55 P = 0.41 P = 0.37 P = 0.91 P = 0.86
*Always = at 100% of assessed visits; never = at 0% of assessed visits; sometimes = .0% and ,100% of assessed visits.
†Average across all visits.
Ammassari et al J Acquir Immune Defic Syndr  Volume 79, Number 4, December 1, 2018
486 | www.jaids.com Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
virological failure than treatment interruption, can probably
be explained by the fact that treatment interruptions $5 days
were seen in less than 0.7% of visits. Indeed, over a 30-day
period, missing 1 dose on 7 consecutive days (clustered
missed doses) will not have the same impact as missing 7
doses on single independent days (interspaced missed
doses).18 Of interest, in our study, unplanned treatment
interruptions were very infrequent, increased with prolonged
follow-up, but with no differences between treatment arms.
This could reﬂect treatment fatigue or some interfering social/
personal events independent of ARV regimen. In our study,
given the short plasma half-life of RAL, even short-term RAL
interruptions could have led to ineffective intracellular
concentrations in some patients, even with high levels of
average adherence.
In the subgroup of patients with baseline CD4+ ,200/
mmc and HIV-1 RNA .100.000 copies per milliliter, there
were no signiﬁcant associations of adherence with virological
failure or the primary endpoint, and no signiﬁcant difference
between the arms. In the RAL + DRV/r arm, we noted
a decreased hazard ratio in this speciﬁc patient group for all 4
adherence measures compared with all patients in this arm,
and to participants in the TDF/FTC + DRV/r arm suggesting
that in this subgroup, good adherence might be more relevant
than in the TDF/FTC + DRV/r arm; however, P values were
not signiﬁcant. Based on this result, the higher rate of
virological failure in the subgroup of patients with baseline
CD4+ ,200/mm3 and HIV-1 RNA .100,000 copies per
milliliter found at the explanatory post hoc analysis was not
explained by differences in adherence. However, it should be
considered that numbers were small in this subgroup, and the
trial was not speciﬁcally powered to conduct subgroup
analyses to this regard. In fact, it is possible that, rather than
an absence of effect, the sample size was not large enough to
detect a signiﬁcant association between adherence levels and
inferiority of RAL + DRV/r in respect to TDF/FTC + DRV/r
in patients with worse viroimmunological status (ie, CD4
cells ,200/mm3 or CD4 cells ,200/mm3 and HIV RNA
.100,000 copies per milliliter).
The best way to measure adherence, from a clinically
relevant standpoint, is still debated.19,20 Patient self-reported
measures of ARV adherence can greatly vary in terms of item
content, format, or period investigated.21 Nevertheless, the
method is frequently used because of utilization ease, low
costs, nonintrusiveness, and wide applicability. Overestima-
tion of real adherence rates due to desirability bias may be of
concern for the validity of self-reported adherence measure
but applies in a randomized clinical trial to both treatment
arms equally. An analysis of 1247 HIV-positive subjects
participating in multicenter medication adherence-promotion
TABLE 3. Adherence and Time to Virological Failure or Primary Endpoint: (1) Overall and (2) in the Subgroup Baseline CD4 Cells
,200/mmc and HIV-1 RNA $100,000 Copies per Milliliter
Adherence Measure
Adherence and Time to Virological failure* Adherence and Time to Primary Endpoint†
RAL + DRV/r
TDF/FTC +
DRV/r Overall RAL + DRV/r
TDF/FTC +
DRV/r Overall
Doses taken in the last
4 days: $95%
versus ,95%
Overall 0.75 (0.37–1.52),
P = 0.423
0.38 (0.19–0.77),
P = 0.007
0.54 (0.33–0.89),
P = 0.015, Pint = 0.19
0.64 (0.34–1.23),
P = 0.185
0.46 (0.23–0.90),
P = 0.024
0.55 (0.34–0.87),
P = 0.012, Pint = 0.47
CD4 , 200 and
RNA . 100,000
0.46 (0.11–2.03),
P = 0.307
0.62 (0.08–4.86),
P = 0.645
0.50 (0.15–1.65),
P = 0.245, Pint = 0.82
0.42 (0.12–1.45),
P = 0.170
0.70 (0.09–5.45),
P = 0.731
0.47 (0.16–1.35), P =
0.162, Pint = 0.59
No time deviation
versus deviation
Overall 0.89 (0.53–1.50),
P = 0.669
1.43 (0.82–2.50),
P = 0.209
1.10 (0.75–1.60),
P = 0.624, Pint = 0.22
0.75 (0.45–1.26),
P = 0.283
1.35 (0.80–2.28),
P = 0.257
0.99 (0.69–1.42),
P = 0.955, Pint = 0.12
CD4 , 200 and
RNA . 100,000
0.74 (0.29–1.92),
P = 0.536
2.76 (0.71–10.70),
P = 0.143
1.17 (0.56–2.46),
P = 0.676, Pint = 0.12
0.56 (0.23–1.40),
P = 0.216
2.14 (0.63–7.32),
P = 0.226
0.90 (0.45–1.81),
P = 0.771, Pint = 0.091
No interruption versus
interruption
Overall 1.05 (0.42–2.62),
P = 0.915
2.22 (0.69–7.12),
P = 0.182
1.50 (0.73–3.09),
P = 0.267, Pint = 0.33
0.79 (0.36–1.74),
P = 0.564
1.48 (0.59–3.70),
P = 0.404
1.08 (0.59–1.96),
P = 0.804, Pint = 0.31
CD4 , 200 and
RNA . 100,000
1.28 (0.17–9.67),
P = 0.809
0.97 (0.12–7.79),
P = 0.980
1.17 (0.28–4.95),
P = 0.832, Pint = 0.89
0.53 (0.15–1.81),
P = 0.310
1.17 (0.15–9.22),
P = 0.884
0.67 (0.23–1.93),
P = 0.460, Pint = 0.49
VAS: $95% versus
,95%
Overall 0.65 (0.32–1.32),
P = 0.236
1.03 (0.41–2.60),
P = 0.949
0.78 (0.45–1.37),
P = 0.391, Pint = 0.44
0.55 (0.29–1.06),
P = 0.073
0.98 (0.42–2.28),
P = 0.962
0.70 (0.42–1.17),
P = 0.175, Pint = 0.30
CD4 , 200 and
RNA . 100,000
0.83 (0.19–3.64),
P = 0.810
0.82 (0.10–6.54),
P = 0.853
0.86 (0.26–2.85),
P = 0.805, Pint = 0.96
0.45 (0.15–1.34),
P = 0.150
0.98 (0.12–7.70),
P = 0.984
0.57 (0.22–1.48),
P = 0.247, Pint = 0.48
*Analysis included 770 patients with 111 virological failures based on a separate Cox model for each adherence measure. Pint: P value for the interaction adherence level · arm.
†Analysis included 763 patients with 122 failures based on a separate Cox model for each adherence measure. Pint: P value for interaction randomization arm · adherence.
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trials showed that self-report overestimated actual medication
ingestion by an average of 26% points compared with
electronic drug monitoring.22 Furthermore, the patient’s recall
of medication intake in answering diverse adherence ques-
tions may reﬂect not only drug ingestion but also other
aspects, such as patient’s perception and/or satisfaction to
treatment. In fact in our study, the rather low concordance
observed between categories of self-reported number of doses
taken in the last 4 days and 30-day adherence at the VAS
(88%) is likely to be due to these aspects. Medication event
monitoring system, the gold standard in some studies, can by
itself represent an interventional bias and could be associated
to poor adherence to the device that measures the adherence
behavior.23 Evaluation of differences between adherence
measures remains an interesting aspect to investigate, and
methods for cocalibration of different instruments are
needed.24 The fact that adherence worsened over time in
our results is consistent with previously reported data.25
Our results show that nonwhite ethnicity was associated
with lower adherence and rate of virological failure or
primary endpoint occurrence. Lower adherence in nonwhite
patients cared for in Australian centers has been associated
with social and cultural issues, independently of regimen
composition.26 Complying to a twice-daily regimen might be
TABLE 4. Determinants of Adherence in Multivariable Analyses (GEE Models)
Doses Taken in the Last 4 days Doses Taken in the Last 4 days Time Deviation Interruption VAS VAS
‡95% Versus ,95%
,80%
No Versus Yes No Versus Yes ‡95% Versus ,95%
,80%,
80%–94.9% 80%–94.9%
95%–99.9% 95%–99.9%
100% 100%
Sex
Male Ref Ref Ref Ref Ref Ref
Female 0.87 (0.52–1.48) 0.71 (0.37–1.34) 0.84 (0.57–1.23) 0.79 (0.44–1.42) 1.72 (0.89–3.31) 1.06 (0.58–1.94)
P = 0.618 P = 0.288 P = 0.366 P = 0.434 P = 0.108 P = 0.840
Age (per 5 yrs) 1.15 (1.06–1.25) 1.15 (1.04–1.27) 1.03 (0.98–1.09) 1.14 (1.04–1.25) 1.21 (1.09–1.33) 1.14 (1.05–1.23)
P = 0.001 P = 0.006 P = 0.197 P = 0.004 P , 0.001 P = 0.002
Ethnicity
White Ref Ref Ref Ref Ref Ref
Nonwhite 0.66 (0.44–1.00) 0.70 (0.42–1.17) 0.64 (0.48–0.86) 0.90 (0.57–1.43) 0.35 (0.22–0.55) 0.52 (0.33–0.84)
P = 0.048 P = 0.176 P = 0.003 P = 0.668 P , 0.001 P = 0.007
Mode of HIV infection
Homosexual/bisexual Ref Ref Ref Ref Ref Ref
Other 0.71 (0.48–1.06) 0.68 (0.42–1.11) 1.17 (0.88–1.54) 1.00 (0.64–1.57) 0.64 (0.41–0.99) 0.82 (0.53–1.26)
P = 0.098 P = 0.125 P = 0.275 P = 0.997 P = 0.043 P = 0.370
Baseline CD4+: (Per 100
cells/mmc)
0.91 (0.80–1.04) 0.89 (0.75–1.05) 0.96 (0.89–1.05) 0.90 (0.79–1.03) 0.93 (0.80–1.08) 0.87 (0.76–1.00)
P = 0.156 P = 0.159 P = 0.383 P = 0.134 P = 0.344 P = 0.051
Baseline HIV-1 RNA
(per log10 copies per
milliliter)
1.01 (0.78–1.32) 0.99 (0.72–1.37) 1.05 (0.89–1.25) 0.99 (0.75–1.30) 0.95 (0.69–1.30) 1.14 (0.88–1.48)
P = 0.924 P = 0.952 P = 0.536 P = 0.923 P = 0.748 P = 0.320
Country
France Ref Ref Ref Ref Ref Ref
Belgium 0.75 (0.44–1.26) 0.62 (0.32–1.18) 1.03 (0.70–1.53) 0.87 (0.47–1.62) 0.62 (0.34–1.14) 0.67 (0.35–1.28)
Germany 2.62 (1.43–4.80) 3.64 (1.80–7.37) 1.61 (1.15–2.27) 2.04 (1.13–3.68) 2.45 (1.20–5.04) 1.19 (0.73–1.94)
Spain 0.98 (0.60–1.60) 0.97 (0.51–1.85) 0.75 (0.51–1.12) 0.64 (0.37–1.11) 0.72 (0.38–1.37) 0.62 (0.35–1.13)
United Kingdom 2.82 (1.26–6.30) 3.72 (1.46–9.51) 1.28 (0.89–1.83) 0.84 (0.49–1.45) 1.07 (0.57–2.00) 0.93 (0.52–1.63)
Italy 2.24 (1.19–4.21) 2.67 (1.31–5.45) 1.49 (1.08–2.07) 1.73 (0.97–3.08) 0.89 (0.52–1.55) 0.71 (0.43–1.18)
Other 0.98 (0.61–1.56) 1.04 (0.58–1.86) 1.15 (0.83–1.59) 1.20 (0.70–2.08) 1.14 (0.64–2.03) 0.98 (0.60–1.61)
P = 0.0004 P , 0.001 P = 0.0052 P = 0.0140 P = 0.0371 P = 0.3028
Study arm
RAL + DRV/r Ref Ref Ref Ref Ref Ref
TDF/FTC + DRV/r 1.32 (0.97–1.81) 1.55 (1.05–2.29) 1.19 (0.97–1.45) 0.78 (0.57–1.08) 0.99 (0.69–1.40) 1.44 (1.06–1.97)
P = 0.081 P = 0.027 P = 0.094 P = 0.140 P = 0.934 P = 0.020
Study week
04 Ref. Ref. Ref. Ref. Ref. Ref.
12 1.21 (0.84–1.73) 1.23 (0.80–1.88) 0.87 (0.72–1.06) 0.67 (0.44–1.00) 0.89 (0.62–1.28) 0.58 (0.42–0.81)
24 0.90 (0.63–1.29) 0.85 (0.56–1.30) 0.87 (0.70–1.07) 0.57 (0.37–0.89) 0.96 (0.65–1.42) 0.55 (0.40–0.77)
48 0.96 (0.66–1.41) 0.93 (0.59–1.45) 0.89 (0.72–1.10) 0.49 (0.33–0.75) 0.73 (0.50–1.06) 0.37 (0.27–0.52)
96 0.87 (0.60–1.26) 0.82 (0.52–1.27) 0.81 (0.65–1.00) 0.45 (0.30–0.69) 0.73 (0.49–1.09) 0.37 (0.26–0.52)
P = 0.4913 P = 0.4063 P = 0.3899 P = 0.0033 P = 0.3444 P , 0.001
Ammassari et al J Acquir Immune Defic Syndr  Volume 79, Number 4, December 1, 2018
488 | www.jaids.com Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
more problematic in patients faced with poverty, poor
housing, and eating insecurity. Older age was associated with
better adherence, independently of regimen allocated, and
whatever the measure of adherence. Many studies have
documented younger age as a relevant factor associated to
lower adherence, emphasizing the need for targeted counsel-
ing on adherence barriers in this population.27–29
With regards to study limitations, the most important
issue as mentioned above is that, besides missing adherence
data, the study was not speciﬁcally powered to conduct
subgroup analyses. Therefore, it is not possible to determine
whether our ﬁndings substantiate the hypothesis of efﬁcacy
difference between TDF/FTC + DRV/r and RAL + DRV/r in
ART-naive subjects with worse baseline viroimmunological
status or whether they are due to insufﬁcient power for
subgroup analyses. Furthermore, disparities in clinical man-
agement across centers may have impacted adherence
behaviors, and we cannot exclude the fact that some non-
adherence behaviors may have been missed because of the
infrequent collection of self-administered questionnaires.
Finally, measurement of adherence by patient self-report
can overestimate medication intake, but more objective
measures such as plasma drug concentrations or medication
event monitoring system have other disadvantages, such as
“white coat adherence” close before clinic visit or intrusive-
ness in the patient’s daily life. On the contrary, one of the
main strengths of the study is the evaluation of adherence to
ARVs within a randomized clinical trial comparing of TDF/
FTC + DRV/r versus RAL + DRV/r in a large patient
population that was followed up for a considerable period.
Second, as the study protocol did not include adherence
interventions, the results provide valuable information about
adherence dynamics in ARV-naive HIV-infected persons and
its relation to virological outcome.
In conclusion, in this randomized study comparing 2
strategies of ﬁrst-line ART, average adherence assessed by
patient self-report was high in both arms, but slightly and
signiﬁcantly better for TDF/FTC + DRV/r compared with RAL
+ DRV/r. Only adherence ,95% in the last 4 days was
associated to a higher risk of virological failure, with no
differences between the 2 arms. Adherence levels were not
different in baseline CD4+ and HIV RNA strata across arms, and
there was no convincing evidence that higher failure rate in the
RAL + DRV/r arm in the subgroup of patients with baseline
CD4+ ,200/mmc and HIV-1 RNA .100,000 copies per
milliliter found at the explanatory post hoc analysis of the
NEAT001/ANRS143 trial was caused by adherence differences.
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